Shorter chemo with targeted drugs for low-risk DLBCL
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial compares two different lengths of chemotherapy (4 cycles vs. 6 cycles) combined with two targeted drugs, polatuzumab vedotin and rituximab, for people with newly diagnosed DLBCL who have a low-risk score. The goal is to see if a shorter treatment works just as well with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a new diagnosis of diffuse large B-cell lymphoma (DLBCL) that has not been treated yet.
- You are between 18 and 80 years old.
- Your lymphoma has a low-risk score (IPI 0 or 1).
- You are in fairly good health (able to take care of yourself, ECOG 0-2).
- You have at least one lymphoma spot that can be measured on a PET/CT scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a combination of three drugs (pola, Rituxan, and lenalidomide) for older adults (70+) with a common type of lymphoma (DLBCL) who are not well enough for standard chemotherapy. The goal is to see if this gentler treatment works well for patients who are less fit.
This trial tests a new combination of drugs (Pola-ZR2P) for people with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) who have not had chemotherapy yet. It aims to see if this treatment is safe and effective.
This study compares three different drug combinations for people with untreated DLBCL. One group gets a standard combination (pola-RCHP), another gets that plus a targeted pill (like orelabrutinib or venetoclax), and a third gets the standard chemo without the targeted antibody. The goal is to see which approach works best and is safest.
This trial tests a new combination of targeted therapies and chemotherapy for older adults with a diagnosis of diffuse large B-cell lymphoma. The goal is to see if this approach is safe and effective for people who may not be able to tolerate standard treatment.
This trial tests a combination of two targeted therapies, polatuzumab vedotin and glofitamab, for people with DLBCL that either came back within 12 months of R-CHOP or never went away. The goal is to see if this two-drug approach can help when standard chemotherapy has not worked well.
Hear when a new DLBCL - Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.